Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib.

Baricitinib is a Janus kinase inhibitor that has been approved by the US Food and Drugs Administration for the treatment of severe alopecia areata (AA) in adults. However, the clinical trials that demonstrated the efficacy of baricitinib in the treatment of severe AA did not include men aged > 60 years or women aged > 70 years. We retrospectively assessed the efficacy and safety of baricitinib in 14 patients aged ≥ 65 years with moderate-to-severe AA.

Alopecia Areata Mimicking Frontal Fibrosing Alopecia.

Alopecia areata (AA) is an autoimmune nonscarring alopecia that has variable clinical patterns, most commonly patchy disease. We report a case of AA with unusual involvement of the frontal hairline, mimicking frontal fibrosing alopecia (FFA), a form of scarring alopecia. Dermoscopic findings and response to treatment favored a diagnosis of AA.

Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients.

Background: The major concern regarding the use of low-dose oral minoxidil (LDOM) for the treatment of hair loss is the potential risk of systemic adverse effects.

Objective: To describe the safety of LDOM for the treatment of hair loss in a large cohort of patients.

Methods: Retrospective multicenter study of patients treated with LDOM for at least 3 months for any type of alopecia.

Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: A retrospective study.

Background: Alopecia areata (AA) is an autoimmune hair loss condition that affects people of all ages. Early age of onset and prolonged disease duration indicate poor prognosis. Janus kinase inhibitors are being investigated in phase 3 clinical trials in adolescents and adults with AA OBJECTIVE: To evaluate the use of oral tofacitinib in pre-adolescent patients with AA.

Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab.

Lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) are lymphocytic, cicatricial alopecias. Clinically, LPP presents with multifocal patchy alopecia, while FFA, considered a variant of LPP, results in hairline recession. Frontal recession in FFA may progress as far as the mid-scalp and infrequently beyond.

Bitemporal alopecia areata.

Alopecia areata has various clinical presentations, some of which have recognised prognostic significance. We report five cases of bitemporal alopecia areata, with involvement of the frontal hairline, the therapeutic approach for each case and possible differential diagnoses to also consider.